Trial Profile

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amisulpride (Primary) ; Raclopride
Indications Schizophrenia
Focus Pharmacodynamics
Sponsors LB Pharmaceuticals

Most Recent Events

11 Jan 2022 Status changed from active, no longer recruiting to completed.
07 Dec 2021 According to a LB Pharmaceuticals media release, results from this study were presented at the 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP).
07 Dec 2021 Results presented in a LB Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com